Andrew Kay

Renovo Plc manufactures and distributes pharmaceutical products. The biopharmaceutical company develops novel pharmaceuticals products to prevent and reduce scarring in the skin, cardiovascular system, eye, central nervous system, internal adhesions, ligaments and systemic fibrotic disorders. The company was founded in 2000 and is headquartered in Manchester, United Kingdom.

Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway.

Ultimate Finance Holdings Ltd. provides various SME lending products. The company was founded by Mark William James Ferguson and Sharon O'Kane in 1998 and is headquartered in Bradley Stoke, the United Kingdom.

Wilson Therapeutics AB engages in the development of novel therapies for patients with rare copper-mediated disorders. The company was founded on April 25, 2012 and is headquartered in Stockholm, Sweden.

Blueberry Therapeutics Ltd. engages in the development of innovative medicines. It offers nanomedicine, anti infection and anti microbial, anti inflammatory bowel diseases, acne, dermatitis and wound medicines. The company was founded by John Ridden and Mike Davies and is headquartered in Macclesfield, the United Kingdom.

NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom.